替比夫定阻断HBV DNA高载量孕妇母婴传播的疗效和安全性观察

孙维会; 初蕾蕾; 柳维林; 郝岸华; 马磊; 万强; 任蓉; 辛永宁

doi:10.3969/j.issn.1001-5256.2013.08.011

替比夫定阻断HBV DNA高载量孕妇母婴传播的疗效和安全性观察

DOI: 10.3969/j.issn.1001-5256.2013.08.011

1. 青岛市城阳人民医院感染科
2. 青岛市市立医院消化内二科
3. 青岛市消化疾病重点实验室
4. 中国海洋大学医药学院

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3452
- HTML全文浏览量: 17
- PDF下载量: 673
- 被引次数: 0
出版历程
- 收稿日期: 2012-11-06
- 出版日期: 2013-08-20

Efficacy and safety of telbivudine in preventing mother-to-infant transmission of HBV in pregnant women with high HBV DNA load

摘要

摘要:
目的评价妊娠早期(12周)应用替比夫定阻断高病毒载量孕妇母婴传播的疗效和安全性。方法选择妊娠12周慢性乙型肝炎孕妇80例,病毒载量均超过1×107拷贝/ml。按患者意愿分治疗组(替比夫定组)38例和对照组42例,治疗组口服替比夫定600 mg,1次/d,加用复方甘草酸苷保肝治疗,替比夫定服用至产后12周;对照组不给予抗病毒药物,只给予复方甘草酸苷保肝治疗。两组新生儿出生后均接种乙型肝炎免疫球蛋白200 IU与乙型肝炎疫苗20μg。婴儿7月龄时HBsAg及HBV DNA阳性者为HBV宫内感染。观察两组患者母体HBV DNA水平的变化情况和新生儿HBsAg的阳性率。对两组HBsAg阳性率的差异分析采用卡方检验;组间比较行t(t’)检验,治疗前后的比较采用配对t检验。结果至分娩前,替比夫定组孕妇HBV DNA、ALT水平明显下降。替比夫定组HBV DNA载量于治疗2周后迅速下降,之后缓慢下降直至分娩。替比夫定组服药至分娩前及分娩后12周HBVDNA水平明显降低(t=29.15、40.06,P<0.01),而对照组无明显变化(p>0.05)。替比夫定组分娩前及分娩后12周HBV D...
- 肝炎病毒,乙型 /
- 替比夫定 /
- 妊娠 /
- 疾病传播,垂直
Abstract:
Objective To evaluate the efficacy and safety of telbivudine given from the 12th week of gestation in preventing mother-to-infant transmission of hepatitis B virus (HBV) in pregnant women with high HBV DNA load.Methods Eighty pregnant women (at 12 weeks of gestation) with chronic hepatitis B, who had a HBV DNA load higher than 1.0×107 copies/ml, were enrolled.The patients were divided into two groups according to their personal preferences: treatment group (n=38) and control group (n=42) .The treatment group received oral telbivudine (600 mg) once daily until 12 weeks after delivery and was administered compound glycyrrhizin for liver protection, while the control group was given compound glycyrrhizin for liver protection alone.All infants in both groups were vaccinated with hepatitis B immunoglobulin (200 IU) and HBV vaccine (20 μg) after birth.The mother-to-infant transmission of HBV was indicated by the presence of HBsAg and HBV DNA in infants at 7 months after birth.The HBV DNA levels in these women were measured, and the positive rate of HBsAg in infants was determined.The difference in positive rate of HBsAg was analyzed by chi-square test;the between-group comparison was analyzed by group t (t′) -test, and the before-after comparison was analyzed by paired t-test.Results The treatment group showed significantly decreased HBV DNA and alanine aminotransferase levels before delivery.The HBV DNA load of treatment group dropped rapidly after 2 weeks of treatment and then decreased slowly until delivery.The treatment group had significantly decreased HBV DNA levels before delivery and at 12 weeks after delivery (t=29.15, P<0.01;t=40.06, P<0.01) but="" the="" control="" group="" showed="" no="" significant="" changes="" p="">0.05) .The treatment group had significantly lower HBV DNA levels than the control group before delivery and at 12 weeks after delivery (P<0.01) .No infants in the treatment group were HBV-positive, versus a positive rate of 14.3% in the control group (χ2=3.99, P<0.05) .No adverse events occurred in the mothers or their infants in treatment group, but two cases of severe hepatic dysfunction were found in the control group.There were no significant differences between the two groups in terms of cesarean section rate, adverse pregnancy rate, and postpartum hemorrhage rate as well as the gestational age, body weight and height, and Apgar scores of neonates.Conclusion Telbivudine given from the 12th week of gestation can significantly decrease the serum HBV DNA level in peripheral blood among pregnant women with high HBV DNA load and reduce the infection rate of HBV in neonates, and it has high tolerability and safety.
- hepatitis B virus /
- telbivudine /
- pregnancy /
- disease transmission

HTML全文

参考文献(18)

[1]JONAS MM.Hepatitis B and pregnancy:an underestimated issue[J].Liver Int, 2009, 29 (Suppl 1) :133-139.

[2]ZHU ZQ, ZHANG XH, ZHANG LY, et al.Correlation analysis be-tween plasma and colostrum viral load in hepatitis B virus carrierpuerperae[J].Int J Virol, 2012, 19 (2) :49-52. (in Chinese) 朱召芳, 张晓红, 张丽岩, 等.乙肝病毒携带产妇血浆与初乳中病毒含量的相关性研究[J].国际病毒学杂志, 2012, 19 (2) :49-52.

[3]LIN J, LIAO S, HAN LJ, et al.Correlation neonatal hepatitis Band maternal serum hepatitis B virus DNA copies[J].Pediatr Res, 2000, 47:342.

[4]LI XM, SHI MF, YANG YB, et al.Effect of hepatitis B immuno-globulin on interruption of HBV intrauterine infection[J].World JGastroenterol, 2004, 10 (21) :3215-3217.

[5]HOOFNAGLE JH, DOO E, LIANG TJ, et al.Management of hep-atitis B:summary of a clinical research workshop[J].Hepatology, 2007, 45 (4) :1056-1075.

[6]TRAN TT.Management of hepatitis B in pregnancy:weighing the options[J].Cleve Clin J Med, 2009, 76 (Suppl 3) :s25-s29.

[7]HAN GR, CAO MK, ZHAO W, et al.A prospective and open-label study for the efficacy and safety of telbivudine in regnancy forthe prevention of perinatal transmission of hepatitis B virus infection[J].J Hepatol, 2011, 55 (6) :1215-1221.

[8]CHEN XQ, YAO ZC, WU LP, et al.Clinical study on telbivudinein preventing mother-to-infant HBV transmission during the latepregnancy[J].J Clin Hepatol, 2011, 27 (2) :52-54. (in Chi-nese) 陈晓勤, 姚展成, 吴丽萍, 等.妊娠晚期应用替比夫定阻断乙型肝炎病毒垂直传播的临床观察[J].临床肝胆病杂志, 2011, 27 (2) :52-54.

[9]ZENG Y, ZHANG S, LOU G, et al.Clinical study of telbivudineto interrupt intrauterine transmission of hepatitis B virus[J].Chin JClin Pharmacol Ther, 2010, 15 (4) :443-445. (in Chinese) 曾艳梅, 张思泉, 娄国强, 等.替比夫定阻断乙肝病毒宫内感染的临床研究[J].中国临床药理学与治疗学杂志, 2010, 15 (4) :443-445.

[10]ZHANG YF, HU YH.Efficacy and safety of telbivudine in preven-ting mother-to-infant HBV transmission[J].ADRJ, 2010, 12 (3) :157-159. (in Chinese) 张彦芳, 胡玉红.替比夫定阻断乙型肝炎病毒母婴传播的疗效和安全性[J].药物不良反应杂志, 2010, 12 (3) :157-159.

[11]HAN GR, JIANG HX, WANG GJ, et al.Efficacy and safety of tel-bivudine in pregnant women to prevent perinatal transmission of hep-atitis B virus[J].Chin J Hepatol, 2012, 20 (3) :201-205. (inChinese) 韩国荣江红秀王根菊, 等.替比夫定对乙型肝炎病毒高载量孕妇母婴传播的阻断效果及其安全性[J].中华肝脏病杂志, 2012, 20 (3) :201-205.

[12]PAN CQ, HAN GR, JIANG HX, et al.Telbivudine prevents verti-cal transmission from HBeAg-positive women with chronic hepatitisB[J].Clin Gastroenterol Hepatol, 2012, 10 (5) :520-526.

[13]AI MH, YU JP, XIAO S.Therapeutic effects of lamivudine in theinterruption of intrauterine HBV infection in pregnant women withhigh HBV DNA levels at late pregnancy[J].Chin Med Herald, 2012, 9 (16) :83-84. (in Chinese) 艾美华, 于建鹏, 肖苏.妊娠晚期应用拉米夫定阻断血清高HBV DNA水平孕妇乙型病毒宫内感染的疗效观察[J].中国医药导报, 2012, 9 (16) :83-84.

[14] Chinese Society of Hepatology and Chinese Society of Infectious Disea-ses, Chinese Medical Association.The guideline of prevention andtreatment for chronic hepatitis B[J].J Clin Hepatol, 2006, 22 (1) :3-15. (in Chinese) 中华医学会肝病学分会, 感染病学分会.慢性乙型肝炎防治指南[J].临床肝胆病杂志, 2006, 22 (1) :3-15.

[15]YANG YB, LI XM, HOU HY, et al.The relation between maternalHBV infectivity and intrauterine infection[J].Chin J Birth HealthHeredity, 2004, 12 (2) :52-57. (in Chinese) 杨越波, 李小毛, 侯红瑛, 等.母体HBV传染性与宫内感染的探讨[J].中国优生与遗传杂志, 2004, 12 (2) :52-57.

[16]BAI GQ, LI SH, YUE YF, et al.The study on role of peripheralblood mononuclear cell in HBV intrauterine infection[J].Arch Gy-necol Obstet, 2011, 283 (2) :317-321.

[17]BRIDGES EG, SELDEN JR, LUO S.Nonclinical safety profile oftelbivudine, a novel potent antiviral agent for treatment of hepatitisB[J].Antimicrob Agents Chemother, 2008, 52 (7) :2521-2528.

[18]SINHA S, KUMAR M.Pregnancy and chronic hepatitis B virus in-fection[J].Hepatol Res, 2010, 40 (1) :31-48.

施引文献

资源附件(0)

访问统计